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Controlled Cortical Impact Traumatic Brain Injury in
3xTg-ADMice Causes Acute Intra-Axonal Amyloid-
Accumulation and Independently Accelerates the
Development of Tau Abnormalities
Hien T. Tran,1 FrankM. LaFerla,4David M. Holtzman,1,2,3 and David L. Brody1,3
1Department of Neurology, 2Department of Developmental Biology and Anatomy, and 3Hope Center for Neurological Disorders, Washington University in
St. Louis, St. Louis, Missouri 63110, 4Department of Neurobiology and Behavior, University of California, Irvine, California 92697
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized pathologically by progressive neuronal loss, extracellular
plaques containing the amyloid- (A) peptides, and neurofibrillary tangles composed of hyperphosphorylated tau proteins. A is
thought to act upstream of tau, affecting its phosphorylation and therefore aggregation state. One of the major risk factors for AD is
traumatic brain injury (TBI). Acute intra-axonal A and diffuse extracellular plaques occur in30%of human subjects after severe TBI.
Intra-axonal accumulations of tau but not tangle-like pathologies have also been found in these patients. Whether and how these acute
accumulations contribute to subsequent AD development is not known, and the interaction between A and tau in the setting of TBI has
not been investigated. Here, we report that controlled cortical impact TBI in 3xTg-AD mice resulted in intra-axonal A accumulations
and increased phospho-tau immunoreactivity at 24 h and up to 7 d after TBI. Given these findings, we investigated the relationship
between A and tau pathologies after trauma in this model by systemic treatment of Compound E to inhibit -secretase activity, a
proteolytic process required for A production. Compound E treatment successfully blocked posttraumatic A accumulation in these
injured mice at both time points. However, tau pathology was not affected. Our data support a causal role for TBI in acceleration of
AD-relatedpathologies and suggest thatTBImay independently affectA and tauabnormalities. Future studieswill be required to assess
the behavioral and long-term neurodegenerative consequences of these pathologies.
Introduction
Traumatic brain injury (TBI) can increase the risk for subsequent
development of dementia of the Alzheimer’s type (Mortimer et
al., 1991; Nemetz et al., 1999; Plassman et al., 2000; Fleminger et
al., 2003). Pathological hallmarks of Alzheimer’s disease (AD) are
extracellular plaques containing the amyloid- (A) peptides
and neurofibrillary tangles (NFTs) containing hyperphosphory-
lated tau proteins.
Inmousemodels of AD,A pathology appears to be upstream
of tau pathology. Three lines of experimental evidence support
this relationship. First, intracerebral injections of aggregated A
increased tau phosphorylation and therefore numbers ofNFTs in
TauP310L transgenic mice at both local and distant regions (Gotz
et al., 2001). Second, double-transgenic mice expressing both
mutant APP and tau developed greater tau pathology than single
tau transgenicmice (Lewis et al., 2001; Perez et al., 2005; Hurtado
et al., 2010). Third, intracerebral injections of anti-A antibodies
in 3xTg-ADmice reduced bothA and tau pathology. Apathol-
ogy then recurred, followed by later recurrence of tau pathology
(Oddo et al., 2004).
On the other hand, the human pathological literature suggests
that A and tau pathologies may be independent in the setting of
TBI, or at least that the relationship may be more complex. First,
in single severe TBI, intra-axonal A and diffuse extracellular
plaques occurred in about 30% of subjects (Roberts et al., 1991,
1994; Uryu et al., 2007). Intra-axonal accumulations of total and
phospho-tau, but not true NFT pathology, have been docu-
mented in a smaller number of cases (C. Smith et al., 2003; Ikono-
movic et al., 2004; Uryu et al., 2007). In repetitive concussive
TBI resulting in dementia pugilistica or chronic traumatic
encephalopathy, the opposite relationship was found; 100% of
cases reported to date have had widespread NFTs, but a
smaller subset had A pathology (Corsellis and Brierley, 1959;
Corsellis, 1989; Roberts et al., 1990; Tokuda et al., 1991; Ged-
des et al., 1996, 1999; Schmidt et al., 2001; McKee et al., 2009).
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Even when both pathologies were present, there was no indi-
cation that they colocalized.
To investigate the relationship between A and tau patholo-
gies in the setting of TBI,we performed controlled cortical impact
TBI in amousemodel of Alzheimer’s disease, called 3xTg-AD. In
the absence of injury, these mice develop intracellular A accu-
mulation starting at 2 months, intracellular tau immunoreactiv-
ity at 6months, extracellular Adeposition at 15–26months, and
tau-containing neurofibrillary tangles at 26 months (Oddo et al.,
2003, 2006; Mastrangelo and Bowers, 2008). Here, we show that
controlled cortical impact TBI independently results in intra-
axonal A and tau accumulation and increased tau phosphory-
lation in 3xTg-AD mice. This model may be a useful tool for
manymechanistic and preclinical therapeutic investigations into
the association between TBI and Alzheimer’s disease.
Materials andMethods
Animals.Weused 5- to 7-month-old homozygous 3xTg-ADmice (Oddo
et al., 2003) of both sexes on a B6/SJV129 background and wild-type
B6/SJLmice. 3xTg-ADmice used in these experimentswere derived from
founders received from the LaFerla laboratory in 2007. A and tau pa-
thologies have been stable since that time, with no evidence of drift. Mice
were housed in standard cages in a 12 h light/dark cycle and given food
and water ad libitum. All experiments were approved by the animal stud-
ies committee at Washington University in St Louis.
Controlled cortical impact experimental TBI. The experimental TBI
methods used in this study were performed as described previously
(Brody et al., 2007; Mac Donald et al., 2007b). Briefly, mice were anes-
thetized with isoflurane (5% induction, 2%maintenance) and placed on
a stereotaxic frame. After a midline skin incision, a 5 mm left lateral
craniotomywasmade using amotorized drill. Controlled cortical impact
was produced with an electromagnetic impact device using a 3-mm-
diameter metal tip. The impact was centered at 2.7mm lateral tomidline
and 3.0 mm anterior to lambda. Injury severities of 1.0 mm (n 6), 1.5
mm (n 5), and 2.0mm (n 48 total in all experiments) below the dura
were chosen to model mild, mild-moderate, and moderate injuries, re-
spectively. After injury, the impact site was covered with a plastic skull
cap, skin was sutured, andmice were allowed to recover on a heated pad.
Mice were kept at 37°C via a rectal temperature probe and feedback
temperature controller throughout the duration of the surgery (Cell
MicroControls). Temperature control is important because hypother-
mia alone has been reported to cause tau accumulation and hyperphos-
phorylation (Planel et al., 2004). Shammice underwent the same surgical
procedure including anesthesia and craniotomy but were not injured.
Antibodies. Antibodies used are listed in Table 1. To avoid using anti-
mouse secondary antibodies on injured tissues, most monoclonal anti-
bodieswere conjugated to biotin or directly labeled. 3D6was biotinylated
withNHS-LC-biotin fromPierce. Conjugation of 3D6 toAlexa Fluor 596
was done a via commercially available kit (A20185; Invitrogen).
Immunohistochemistry and double immunofluorescence. Immunohis-
tochemical studies were done on paraformaldehyde-fixed, sucrose-
equilibrated 50 m cryostat sections, as described previously (Mac
Donald et al., 2007a,b). All sections were washed with Tris-buffered sa-
line (TBS) between applications of antibody solutions. Antigen retrieval
with 70% formic acid (3 min) was performed for A and phospho-tau
staining. Nonspecific bindingwas blocked by incubation in TBS contain-
ing 0.25% Triton X (TBS-X) and 3% nonfat dry milk (monoclonal anti-
bodies) or 3% serum (polyclonal antibodies) or 5% BSA (phospho-tau
antibodies). The primary antibody was diluted in 1% nonfat dry milk,
1% serum, or 1%BSA inTBS-X.Antibodieswere 3D6 (1g/ml), pan-A
(1 g/ml), A40 (0.5 g/ml), A42 (5 g/ml), APP (0.5 g/ml), neuro-
filament (0.5 g/ml), HT7 (0.2 g/ml), polyclonal tau (1 g/ml), poly-
clonal phospho-tau antibodies (1 g/ml), and PHF1 (1:1000) (Table 1).
Bound antibodies were detected with biotinylated secondary antibodies,
except for 3D6, which was biotinylated. The horseradish peroxidase
method (ABC Elite kit, PK6100; Vector Laboratories) and DAB were
used for visualization of bound antibodies.
In double-labeling studies, primary antibodies were sequentially ap-
plied, followed by Alexa Fluor-conjugated secondary antibodies except
for 3D6, which was conjugated to Alexa Fluor 596. Images were obtained
using LSM 5 Pascal software (Zeiss Physiology Software) coupled to an
LSM Pascal Vario 2 RGB confocal system (Zeiss).
Preparation of tissue homogenates for A detection by human-specific
ELISAs. Separate groups of sham (n 7) and TBI (2.0 mm, n 8) mice
were killed at 24 h after surgery; hippocampi ipsilateral and contralateral
to the impact site (including fimbria and surrounding white matter
tracts) were dounce homogenized in TBS (1:10 w/v). Supernatants were
kept, and pellets were subsequently sonicated in a 1:5 w/v solution of 100
mM sodium carbonate, pH 11, containing 50 mM sodium chloride (car-
bonate lysates). Finally, remaining pellets were homogenized in 1:5 w/v
5M guanidine hydrochloride, rotated at room temperature for 3–4 h
(guan lysates). All buffers used for homogenization contained protease
and phosphatase inhibitor mixtures (Roche). Supernatants and pellets
from all tissue suspensions were obtained by spinning at 13,300 g for
20 min at 4°C. Protein concentrations were determined via the BCA
method (Pierce Biotech). TBS, carbonate, and guanidine lysates pre-
pared above were tested for A contents using a human-specific A
ELISA, as described (Cirrito et al., 2003; Kang et al., 2007). Capture
antibodies were m266 for the total A1-x ELISA, 2G3 for the A1-40
ELISA, and 21F12 for the A1-42 ELISA. The detection antibody was
3D6-biotin. These antibodies were gifts from Eli Lilly and Co.
Preparation of tissue homogenates for tau Western blotting and ELISAs.
Separate groups of sham (n 7) and injured (2.0 mm, n 8) 3xTg-AD
mice were killed at 24 h by rapid decapitation. Bilateral hippocampi were
dissected, immediately frozen, and stored at80°C. Frozen hippocampi
were homogenized in modified RIPA buffer containing protease and
phosphatase inhibitor mixtures (Roche), as described (Cirrito et al.,
2003). After preclearing samples with protein-G Sepharose beads to
remove endogenous mouse IgG, equal amounts of samples were electro-
phoresed on 10% BisTris NUPAGE gels (Invitrogen). After transfer, 0.2-
m-pore nitrocellulose membranes were blocked with 5% nonfat dry
milk in 50 mM Tris, pH 7.6, buffer containing 150 mM NaCl and 0.1%
Tween 20 (TBS-T) for 1 h, and probed with AT8 (1:1000), AT100 (1:
1000), or AT180 (1:1000) in 5% BSA TBS-T overnight at 4°C. Sheep--
mouse HRP (1:12,000; GE Healthcare) and the ECL Advance Western
Blotting kit (GEHealthcare) were used to detect bound antibodies. Blots
were stripped and reprobed for total tau using Tau46 antibody (1:1000).
Table 1. Summary of antibodies used in this study
Protein Antibody Epitope Host/application Source
A 3D6 aa 1–5 requiring
free N terminus
Mouse/IHC, ELISA Eli Lilly and Co.
m266 aa 13–28 Mouse/ELISA Eli Lilly and Co.
2G3 aa 35–40 Mouse/ELISA Eli Lilly and Co.
21F12 aa 33–42 Mouse/ELISA Eli Lilly and Co.
panA aa 15–30 Rabbit/IHC Invitrogen
A40 aa 34–40 Rabbit/IHC Invitrogen
A42 aa 36–42 Rabbit/IHC Chemicon
APP APP Full-length, C terminal Rabbit/IHC, WB Invitrogen
Tau HT7 panTau Mouse/IHC Pierce
pAb Tau panTau Sheep/IHC Pierce
Tau46 panTau Mouse/WB Cell Signaling
AT8 pS199, pS202, pT205 Mouse/WB Pierce
AT100 pS212, pT214 Mouse/WB Pierce
AT180 pT231 Mouse/WB Autogen Bioclear
S199 pS199 Rabbit/IHC Invitrogen
T205 pT205 Rabbit/IHC Invitrogen
T231 pT231 Rabbit/IHC Invitrogen
S396 pS396 Rabbit/IHC Invitrogen
S422 pS422 Rabbit/IHC Invitrogen
PHF1 pS396/pS404 Mouse/IHC Dr. P. Davies
Neurofilament NF-L NF-L 68kD Mouse/IHC Sigma
Tubulin -Tubulin -Tubulin/C terminal Mouse/WB Sigma
aa, Amino acids; IHC, immunohistochemistry; WB, Western blot.
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Blots were scanned, and densitometry was performed via Image J (NIH).
Total and phospho-S199 tau ELISAs were performed per the manufac-
turer’s instructions (Invitrogen).
Preparation of tissue homogenates for Western blotting of APP. Bilateral
cerebellar tissue was homogenized in modified RIPA buffer containing
protease inhibitor mixtures (Roche), as described (Cirrito and Holtz-
man, 2003). Protein concentrations were determined via the BCA
method (Pierce Biotech). Equal amounts of samples were electropho-
resed on 4–12% BisTris NuPAGE gels (Invitrogen) and transferred to
0.2-m-pore nitrocellulose membrane. After
transfer, membranes were blocked in 3% non-
fat dry milk in TBS-T for 1 h at room temper-
ature. After washing in TBS-T three times, 5
min each, membranes were incubated with
polyclonal APP antibody (0.25 g/ml) in
blocking buffer overnight at 4°C. Bound anti-
bodies were detected with HRP-conjugated
donkey--rabbit IgG (1:10,000; GE Health-
care) and the ECL Advance Western Blotting
detection kit (GE Healthcare). Blots were
stripped and reprobed with anti--tubulin (1
g/ml) for loading control. Images were taken
on film and scanned.
Compound E treatment. To prevent post-
traumatic intra-axonal A accumulation,mice
were treated with intraperitoneal injections of
vehicle or Compound E (CmpE), a small-
molecule inhibitor of -secretase (10 mg/kg;
Axxora) (Seiffert et al., 2000; Olson et al., 2001;
Grimwood et al., 2005; Yang et al., 2008; Yan et
al., 2009). One group of mice received CmpE
(n 8) or 0.8%DMSO vehicle (n 7) starting
at 1 h before injury, then again at 5, 11, and 17 h
after injury. These mice were killed 24 h after
injury. Another group of mice received 4
CmpE (n 7) or vehicle (n 7) injections in
the first 24 h as noted above, followed by injec-
tions twice daily until 7 d after injury. A total of
10 mg/kg Compound E was used because this
dose has been shown to inhibit cortical
-secretase activity in guinea pigs by 71 4%,
measured ex vivo (Grimwood et al., 2005). Fur-
thermore, the frequent dosing regimen was
used because of the short half-life of Com-
pound E: 5–6 h (Yan et al., 2009). Last, this
relatively high dose was also chosen because of
the presence of the presenilin1 (PS1) M146L
mutation in 3xTg-AD mice, as PS1 mutations
have been shown to have diminished response
to -secretase inhibition (Czirr et al., 2007).
Mice tolerated these dosing regimens well
without additional weight loss, lethargy, or un-
expected mortality.
Stereological quantification. Stereological
methods were available via StereoInvestigator
version 8.2 software. All assessments were
made by a single investigator (H.T.T.) blinded
to injury status and treatment regimens of ex-
perimental animals. The optical fractionator
method was used for quantification of total
numbers of markers of interest per cubic mil-
limeter of tissue. Details on this stereological
method have been described (Mac Donald et
al., 2007a). Briefly, for quantification of A40-
positive axonal varicosities in ipsilateral fim-
bria and tau-positive somata in ipsilateral
amygdala, a 200 200msampling grid and a
75  75 m counting frame were used. For
quantification of total tau, APP, panA, and
phospho-S199-positive puncta in ipsilateral
fimbria, a 300  300 m grid and a 40  40 m counting frame were
used. For PHF1-positive puncta in the fimbria, a 200 200mgrid and
a 50 50mcounting framewere used. A dissector height of 15mand
guard zones of 2.5mwere used for all measurements. Four sections per
mouse, each separated by 300m,were used for these estimations. These
sections spanned approximately bregma1.06 to1.96 mm (Franklin
and Paxinos, 1997). The spherical probe (also known as “space balls”)
method was used for quantification of the total length of tau immuno-
Figure 1. Controlled cortical impact TBI caused A accumulation in ipsilateral fimbria/fornix of young 3xTg-ADmice.A–C, A
immunohistochemistry from an injured 3xTg-AD mouse, a sham 3xTg-AD mouse, and an injured wild-type mouse, respectively.
Scale bar, 2 mm. D–O, Higher magnification of the ipsilateral fimbria/fornix (A–C, boxes). Scale bar, 50 m. The presence of
intra-axonal A in the ipsilateral fimbria/fornix of amoderately injured 3xTg-ADmousewas confirmed using panA, a polyclonal
antibody against amino acids 15–30 of A (D–F ); 3D6, amonoclonal N-terminus antibody against amino acids 1–5 of A (G–I );
A40, a polyclonal C-terminus antibody against amino acids 35–40 of A (J–L); and A42, a polyclonal C-terminus antibody
against amino acids 35–42 of A (M–O). No A immunoreactivity was observed in sham 3xTg-AD mice and injured wild-type
mice. P, No A immunoreactivity was observed in injured 3xTg-AD mice when primary antibody was omitted. Q, Schematic of
anti-A antibodies used.
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reactive processes in the dorsal contralateral
CA1 region (Mouton et al., 2002). A sampling
grid of 250  250 m and a hemispherical
probe with 17m radius were used. Three sec-
tions per mouse from approximately bregma
1.46 to 2.06 mm were used for this
quantification.
Statistical methods. All data were analyzed
using Prism 5.0 (GraphPad Software). Shapiro-
Wilk normality tests were used to assess the
normal distribution of each data set. Mann–
WhitneyU tests were used to compare levels of
A and phospho-tau in hippocampal lysates of
injured and sham 3xTg-ADmice, since the dis-
tribution of data was not normal. For pairwise
comparisons of quantitative immunochemical
data (e.g., injured vs sham), one-sided Stu-
dent’s t tests were used in these cases because
unidirectional hypotheses were prespecified.
For changes of either A or tau pathology as a
function of injury severities, one-way ANOVAs
with Newman–Keuls post tests were used. Val-
ues are means  SEM. Statistical significance
was set to p 0.05.
Results
Intra-axonal A accumulation after
TBI in 3xTg-AD mice
Acute intra-axonal A accumulation is a
prevalent feature of human traumatic ax-
onal injury (D.H. Smith et al., 2003;Uryu et
al., 2007; Chen et al., 2009). Because of the
age-related intra-axonal A accumulation
in 3xTg AD mice, we hypothesized that
these animals would be useful in the assess-
ment of TBI-related axonal A pathology.
More specifically, we hypothesized that ex-
perimental TBI would accelerate intra-
axonal A pathology in young 3xTg-AD
mice. To test this hypothesis, we subjected
thesemice tocontrolledcortical impactTBI,
as detailed (Brody et al., 2007). Mice were
subjected to moderately severe injury: 2.0
mm below the dura. This resulted in signif-
icant hippocampal damage and behavioral
deficits but low mortality, as described
(Brody et al., 2007).Mice were killed at 24 h
after TBI; their brains were then processed
and examined immunohistochemically for A pathology. Negative
controls includedage-matched, sham3xTg-ADmice (whichunder-
went the same anesthesia and surgical procedures but were not in-
jured), injured wild-type B6/SJL mice (2.0 mm), and omission of
primary antibodies. The positive controls forA stainingwere brain
slices from 20-month-old PDAPPmice (Games et al., 1995).
We found A accumulations in pericontusional white matter
of injured, young 3xTg-AD mice. The ipsilateral fimbria/fornix
appeared to have the most prominent A accumulation (Fig.
1A). These A accumulations had spheroidal and “beads-on-a-
string”morphologies, consistent with themorphology of injured
axons (Fig. 1D,G, J,M). The specificity of this A staining was
confirmed with four A-specific antibodies: pan-A against
A15-30 (Fig. 1D), monoclonal 3D6 against A1-5 (Fig. 1G), poly-
clonal C-terminal antibody against A35-40 (Fig. 1 J), and poly-
clonal C-terminal antibody against A35-42 (Fig. 1M). No A
staining was observed when primary antibodies were omitted
(Fig. 1P). No such axonal A pathology was observed in sham
(noninjured), age-matched 3xTg-ADmice (Fig. 1B,E,H,K,N), nor
in injuredwild-typemice (Fig. 1C,F,I,L,O).Awasalsoobserved in
pericontusional hippocampal commissure, corpus callosum, and
the external capsule of injured 3xTg-AD mice, although to a lesser
extent than the fimbria/fornix (data not shown).
To further confirm the immunohistochemical findings, human-
specific A1-x, A1-40, and A1-42 ELISAs were used to assess A
levels in hippocampal lysates of these moderately injured and
sham 3xTg-AD mice. Both ipsilateral and contralateral hip-
pocampi were assessed. These tissues were subjected to serial ho-
mogenization in TBS, carbonate, and 5M guanidine. This serial
homogenization method produces extracts enriched in soluble
A from the extracellular compartment, soluble A from intra-
cellular compartments, and residual insoluble A, respectively.
Although there were similar levels of total A (A1-x) in TBS and
carbonate lysates in both ipsilateral and contralateral hip-
Figure 2. Controlled cortical impact TBI resulted in increased levels of relatively insoluble A in 3xTg-AD mice. Ipsilateral (Ipsi) and
contralateral (Contra)hippocampal tissuesof injured(2.0mm)andsham3xTg-ADmiceweresequentiallyhomogenized inTBS,carbonate,
andguanidinebuffers.TBSandcarbonate lysatescontainmostlysolubleAspecies;guanidine lysatesarecomposedof relatively insoluble
A species.A, Total A levels in TBS lysates of ipsilateral and contralateral hippocampi (Hip) of shamand injuredmice.B, Total A levels
in carbonate lysates of ipsilateral and contralateral hippocampi of sham and injured mice. C, Total A levels in guanidine lysates of
ipsilateral and contralateral hippocampi of sham and injured mice. Significantly more total A levels were observed in ipsilateral hip-
pocampibutnot contralateralhippocampiof injured thanshammice (***p0.0047,Mann–WhitneyU test).D, A1-40.E, A1-42 levels
inguanidinelysatesof ipsilateralhippocampiofshamandinjuredmice.SignificantlymoreA1-40andatrendtowardanincrease inA1-42
were observed in ipsilateral guanidinehippocampal lysates of injured comparedwith shammice (*p0.013; ns, not significant;Mann–
WhitneyU test).n 7–8mice per group. Error bars representmean SEM.
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pocampi (Fig. 2A,B), a significant increase in insoluble total A
was detected in 5M guanidine ipsilateral hippocampal lysates of
injured compared with sham 3xTg-AD (Mann–Whitney U test,
p  0.0047) (Fig. 2C). There was a nonsignificant trend toward
increased guanidine total A levels in the contralateral hip-
pocampi of injuredmice comparedwith sham (Fig. 2C). Further-
more, we found a significant increase in A1-40 and a trend
toward increased A1-42 in the ipsilateral hippocampal lysates of
injured 3xTg-AD mice (Fig. 2D,E). Overall, these data are con-
cordant with the immunohistochemical evidence of intracellular
A accumulation after TBI in these mice.
Previous studies have found that more
severe TBI results inmore APP accumula-
tion in damaged axons (Blumbergs et al.,
1995; Bramlett et al., 1997). Since A is
derived from proteolytic cleavage of APP
and accumulates in axons of 3xTg-AD
mice after TBI, we hypothesized there
would be a correlation between axonal in-
jury severity and extent of A accumula-
tion in these mice. To test this hypothesis,
we performed additional mild (1.0 mm
impact below dura) and mild-moderate
(1.5 mm impact below dura) injuries on
3xTg-AD mice. We compared A- and
APP-labeled axonal pathologies among the
mild, mild-moderate, and moderate (2.0
mm)TBI groupsusing immunohistochem-
istry and stereological quantification.
We found that both APP and A accu-
mulations in pericontusional white mat-
ter were dependent on injury severity in
young 3xTg-ADmice. Specifically, few in-
jured axons stained for APP were found
in the ipsilateral fimbria/fornix of mildly
injured 3xTg-AD mice (1.0 mm) (Fig.
3B,F). Many more APP-stained axonal
varicosities were observed in the same re-
gion in the other injured groups (1.5 and
2.0mm) (Fig. 3C,D,G,H), but none in the
sham injured ones (Fig. 3A,E). Further-
more, we found a parallel relationship be-
tween the extent of the axonal injury and
the amount of intra-axonal A in the fim-
bria/fornix (Fig. 3I–L). Markedly fewer
APP- and A-stained varicosities were
observed in other injured white matter
regions such as the ipsilateral pericontu-
sional hippocampal commissure, ipsilateral
external capsule, and ipsilateral corpus cal-
losum (data not shown). In these other
regions, the extent of both APP and A
staining was similarly dependent on in-
jury severity (data not shown).
To quantitatively characterize the ob-
served relationshipbetween injury severities
and the extent of APP and A accumula-
tions in injured axons of the fimbria/fornix,
we used the optical fractionator stereologi-
cal method. We found significantly more
APP-stained varicosities in the mild-
moderate and moderate TBI groups com-
pared with the mild TBI group (Fig. 3M)
(one-wayANOVA,p0.0001).Therewasatrendtowardanincreasing
number of APP-stained varicosities in the moderate TBI group (2.0
mm) comparedwith themild-moderate TBI group (1.5mm), but this
wasnotstatisticallysignificant(Fig.3M).Asimilarrelationshipbetween
injury severities and numbers of A-stained varicosities was observed:
themoreseveretheinjury,themoreintra-axonalAaccumulation(Fig.
3N)(one-wayANOVA,p0.0005).Therewasastatisticallysignificant
positive correlationbetween thenumbers ofAPP- andA-stained var-
icosities (Fig. 3O) (Pearson r2 0.53, p 0.0015).
To determine definitively whether these accumulations of A
were found within injured axons, we performed double-immuno-
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Figure3. A accumulation variedwith injury severity and colocalizedwithmarkers of axonal injury in 3xTg-ADmice.A–D, APP
immunohistochemistry (IHC) of sham, mildly (1.0 mm), mild-moderately (1.5 mm), and moderately (2.0 mm) injured, young
3xTg-AD mice. Scale bar, 2 mm. E–H, Higher magnification of axonal injury detected by APP IHC in the ipsilateral fimbria (A–D,
boxes). Scale bar, 50m. I–L, Intra-axonal A IHC in the ipsilateral fimbria using pan-A antibody against A15-30.M, Stereo-
logical quantification of numbers of APP-stained varicosities per cubic millimeter of the ipsilateral fimbria as a function of injury
severity. N, Stereological quantification of numbers of A-stained varicosities per cubic millimeter of the ipsilateral fimbria as a
function of injury severity. Error bars represent mean SEM. **p 0.01; ***p 0.005, one-way ANOVAwith Newman–Keuls
post hoc test. ns, Not significant; Mild-Mod, mild-moderate. O, Pearson’s correlation of numbers of A- and APP-stained varicos-
ities in injured fimbria; r 2 0.53, p 0.0015. n 5–6 mice per injury severity. P, Colocalization of A with APP in injured
fimbria of a 3xTg-AD mouse. Scale bar: 50m. Q, Colocalization of Awith neurofilament light chain 68 kDa (NF-L68), another
marker of axonal injury, in injured fimbria of a 3xTg-AD mouse. A was detected with monoclonal 3D6 antibody conjugated to
Alexa Fluor 594 (red). This antibody requires a freeN terminusofA for bindinganddoesnot cross-reactwithAPP.APPandNF-L68
were visualized with a secondary antibody conjugated to Alexa 488 (green).
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fluorescence labeling of A and APP and
separate double immunofluorescence with
the 68 kDa neurofilament light chain sub-
unit, NF-L68. APP and NF-L68 are well
established axonal markers, and accumula-
tions of both proteins are robust signatures
of axonal injury (Gennarelli et al., 1982;
Yaghmai and Povlishock, 1992; Gentleman
et al., 1993; Grady et al., 1993; Christman et
al., 1994; Sherriff et al., 1994; Graham et al.,
1995; Povlishock and Christman, 1995;
Chen et al., 1999; Smith et al., 1999; Stone et
al., 2000, 2001; Marmarou et al., 2005).
They have been shown to extensively colo-
calizewithA in injuredaxons fromhuman
TBI patients (D. H. Smith et al., 2003; Uryu
et al., 2007; Chen et al., 2009). We found
that essentially all A-immunoreactive ax-
onal varicosities in injured 3xTg-AD mice
were also positive for APP and NF-L68 on
confocal microscopy (Fig. 3P,Q). A label-
ing was performed using the monoclonal
anti-A antibody 3D6 directly conjugated
toAlexaFluor 594; 3D6doesnot cross-react
with APP as it requires a free N terminus to
bind (Johnson-Wood et al., 1997). No such
colocalization was observed in sham
3xTg-ADmice (data not shown), nor when
one of the primary antibodies was omitted
(data not shown). Thus, controlled cortical
impact TBI in 3xTg-AD mice reproduced
one of the hallmark features of human
post-TBI neurodegenerative pathology:
intra-axonal A accumulation at sites of
traumatic axonal injury.
To summarize, intra-axonal A accu-
mulationappearedconsistently in3xTg-AD
mice after experimental TBI. This intra-
axonal A appeared to be in a relatively
insoluble form.Moreover, A colocalized
with markers of axonal injury and corre-
lated with severity of axonal injury.
Increased total tau and phospho-tau
immunoreactivity after TBI in
3xTg-AD mice
We next investigated the effects of TBI on
tau accumulation and phosphorylation in
the same injured and sham 3xTg-ADmice.
We first performed immunohistochemistryusingpolyclonal tauan-
tibody (pAbTau) andmonoclonalHT7, which recognize both nor-
mal and hyperphosphorylated human tau. Negative controls
included injured wild-type mice and omission of primary antibod-
ies. Brain slices from 12-month-old 3xTg-ADmice served as a pos-
itive control.
In the pericontusional fimbria/fornix, abnormal punctate tau
immunoreactivity was observed after moderate TBI in 3xTg-AD
mice (Fig. 4A,D).Therewasminimal tau staining in the sameregion
of sham injured mice (Fig. 4B,E) and none in moderately injured
wild-type mice (Fig. 4C,F). Interestingly, there were two additional
regions in which there were marked increases in tau immunoreac-
tivity in injured compared with sham 3xTg-AD mice. These were
the ipsilateral amygdala and contralateral CA1 regions (Fig.
4A,B,G,H, J,K ). Tau immunoreactivity in the amygdala had a
perinuclear cytoplasmic distribution, whereas that in the con-
tralateral CA1 took the appearance of elongated neurites. These
regions are distant from the site of injury but are anatomically
connected to the ipsilateral hippocampus via the ipsilateral fim-
bria/fornix tract (Witter and Amaral, 2004). Similar patterns of
tau staining were observed in injured and sham 3xTg-AD mice
when monoclonal HT7 against total tau was used (Fig. 4M,N-
,P,Q,S,T ). No total tau immunoreactivity was observed in
injured wild-type mice (Fig. 4C,F, I,L,O,R,U). Total tau immu-
noreactivity in the ipsilateral hippocampus was not significantly
affected by TBI in these mice (data not shown).
Next, we examined the effects of varying injury severity on





































Figure 4. Controlled cortical impact TBI accelerated tau pathology in young 3xTg-AD mice. Total tau (independent of phos-
phorylation state)was detectedwith polyclonal total tau antibody (pAb tau) andHT7monoclonal antibody.A–C, pAb tau staining
in injured 3xTg-ADmice, sham 3xTg-ADmice, and injured wild-type mice, respectively. D–F, Higher magnification of the ipsilat-
eral fimbria (A–C, black boxes). G–I, Higher magnification of the ipsilateral amygdala (A–C, green boxes). J–L, Higher magnifi-
cation of the contralateral CA1 (A–C, purple boxes).M–U, Total tau staining using HT7 antibody. More tau-positive puncta were
observed in ipsilateral fimbria of injured3xTg-ADmice comparedwith sham3xTg-ADmice.More tau-positive somatawerepresent
in ipsilateral amygdalaof injured comparedwith sham3xTg-ADmice.More tau-positiveprocesseswerealsoobserved in the contralateral
CA1 of injured comparedwith sham3xTg-ADmice. No tau immunoreactivitywas observed in injuredwild-typemice.
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tau-positive puncta in the ipsilateral fimbria appeared to in-
crease in an injury-severity-dependent manner (Fig. 5F–H ).
There was minimal tau staining in the same region of sham
injured mice (Fig. 5A,E). Only in the moderate TBI group
were there more tau-positive somata in the ipsilateral
amygdala and tau-positive neurites in the contralateral CA1
(Fig. 5I–P). No tau immunoreactivity was observed in injured
3xTg-AD mice when the primary antibody was omitted (data
not shown).
Quantitative analyses of tau immunoreactivity in these re-
gions using stereology confirmed the qualitative histological find-
ings. Therewere significantlymore tau-positive puncta in ipsilateral
fimbria/fornix as the injury becamemore severe (Fig. 5Q) (one-way
ANOVA, p 0.0001). In the moderately injured group (2.0 mm),
there was a significant increase in tau-positive somata in the ipsilat-
eral amygdala comparedwithotherTBIand
sham groups (Fig. 5R) (one-way ANOVA,
p  0.008). Likewise, tau-positive neurite
length density in the contralateral CA1 of
these moderately injured mice was signifi-
cantly greater than the length density in the
other groups (Fig. 5S) (one-way ANOVA,
p 0.0079).
To test whether TBI increased the ex-
tent of tau phosphorylation in 3xTg-AD
mice, we performed additional immuno-
histochemical studies using polyclonal
antibodies against phosphorylated tau in
sham and moderately injured mice. In-
jured mice exhibited more phospho-tau
staining than sham mice for all the
phospho-tau antibodies used. Specifi-
cally, phospho-S199 tau was observed in
ipsilateral hippocampal CA1 and fimbria
of moderately injured mice (Fig. 6A,C).
Immunoreactivity for phospho-T205 was
prominent in ipsilateral fimbria only (Fig.
6E). Tau also appeared to be heavily phos-
phorylated at T231, S396, and S422 in fim-
bria of 3xTg-AD mice after TBI (Fig.
6G,I,K). No phospho-tau immunoreactiv-
itywasobserved in sham3xTg-ADmice at 6
months of age (Fig. 6B,D,F,H,J,L).
To further confirm these findings, sepa-
rate groups of shamandmoderately injured
mice were killed at 24 h by rapid decapita-
tion. Bilateral hippocampi were quickly re-
movedandfrozen.Tissuewashomogenized
in RIPA buffer and subjected to Western
blotting using the monoclonal AT8 anti-
body against phosphorylated tau at S199 or
S202 and T205, the AT100 antibody against
phosphorylated tau at T212 and S214, and
theAT180 antibody against phosphorylated
tau at T231 (Mercken et al., 1992). Blots
were stripped and reprobed with the Tau46
antibody to quantify total tau.
We found marked increases in the
densities of AT8-, AT100-, and AT180-
immunoreactive bands in injured com-
pared with sham 3xTg-ADmice, indicating
an increase in levels of tau phosphorylation
(Fig. 6M–O). Total tau levels in these sam-
ples appeared slightly lower in the injuredmice (Fig. 6M). Overall,
there were approximately twofold increases in the ratio of
AT8-, AT100-, and AT180-immunoreactive phospho-tau
band densities to total tau band densities after TBI in 3xTg-AD
mice (Fig. 6M–O) (Mann–Whitney U test, p  0.05). No such
immunoreactivity for tau was observed when primary anti-
body was omitted (data not shown). No increases in tau phos-
phorylation were detected in contralateral hippocampal
lysates (data not shown).
In summary, experimental TBI caused increased tau immunore-
activity in 6-month-old 3xTg-ADmice.Notably, the spatial distribu-
tion of TBI-related changes in tau immunoreactivity was distinct
from those of postinjury A. Levels of tau phosphorylation were



































































































































Figure 5. Tau pathology varied with injury severity in young 3xTg-AD mice. A–D, pAb Tau immunohistochemistry of sham,
mildly (1.0mm),mild-moderately (1.5mm), andmoderately (2.0mm) injured, young3xTg-ADmice. Scalebar, 2mm.E–H, Higher
magnification of tau staining in the ipsilateral fimbria (A–D, black boxes). Scale bar, 50 m. I–L, Higher magnification of tau
staining in the ipsilateral amygdala (A–D, green boxes).M–P, Highermagnification of tau staining in the contralateral CA1 (A–D,
purple boxes).Q, Stereological quantification of numbers of tau-stained punctate varicosities per cubicmillimeter of the ipsilateral
fimbria as a function of injury severity. R, Stereological quantification of numbers of tau-stained somata per cubic millimeter of the
ipsilateral amygdala as a function of injury severity. S, Stereological quantification of tau-immunoreactive neuritic processes per cubic
millimeter of the contralateral CA1 as a function of injury severity. n 5–6mice per injury severity. Error bars representmean SEM.
*p 0.05; **p 0.01; ***p 0.005, one-wayANOVAwithNewman–Keulspost hoc test.Mild-Mod,mild-moderate.
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Effects of -secretase inhibition on
posttraumatic A accumulation and
tau pathologies
The findings that both A and tau pathol-
ogies were accelerated by controlled corti-
cal impact allowed us the opportunity to
investigate the interaction between A
and tau in the setting of TBI.
To investigate the interaction between
A and tau pathologies, we blocked A
production using a -secretase inhibitor.
-Secretase is one of the canonical en-
zymes required for proteolytic processing
of APP to formA (Selkoe, 2001). If tau is
downstream of A in the setting of TBI,
we expected to see amelioration of tau ab-
normalities after blockingA production.
However, if tau and A are independently
affected by trauma, blocking A produc-
tion should have no effects on tau pathol-
ogy observed after TBI in these mice.
We first confirmed that inhibition of
-secretase blocked intra-axonal A buildup
in 3xTg-ADmice after moderate TBI. We
treated injured mice with CmpE, a small-
molecule inhibitor of -secretase (Seiffert
et al., 2000; Olson et al., 2001; Grimwood
et al., 2005; Yang et al., 2008; Yan et al.,
2009) or DMSO vehicle. Mice received
intraperitoneal injections of 10 mg/kg
CmpE or vehicle at 1 h before injury and
then again at 5, 11, and 17 h after injury.
The frequent dosing regimenwas used be-
cause of the short half-life of CmpE (Yan
et al., 2009). A relatively high dose was
used as a result of the presence of a PS1
mutation in 3xTg-AD mice, since such
mutations may result in diminished re-
sponse to -secretase inhibition (Czirr
et al., 2007). In our first experiment, mice
were killed at 24 h after injury. One group
of CmpE- and vehicle-treated mice was
used for immunohistochemical analysis,
and another group was used for biochem-
ical assessment. For histology, we used
polyclonal antibodyA40 forA immuno-
histochemistry in this experiment since
-secretase cleavage of APP is at the C terminus of A; N-terminal
anti-A antibodies would still recognize the longer APP fragments
remaining after -secretase inhibition. We stained these brains for
APP toassess the extentof axonal injury.Wealsoassessed full-length
-CTFs and-CTFs (APP fragments resulted from cleavage of APP
by - and -secretases, respectively) in the cerebellar lysates of the
samemice viaWestern blot to demonstrate that CmpEwas effective
at inhibiting brain -secretase activity. For the biochemical assess-
ment, we killed mice by rapid decapitation and homogenized ipsi-
lateral hippocampi in RIPA buffers. RIPA lysates of CmpE- and
vehicle-treatedmicewereused todetermine levels ofA40 byELISA.
CmpE treatment almost completely prevented intra-axonal
A accumulation in ipsilateral fimbria of injured 3xTg-AD mice
(Fig. 7A,B). Stereological quantification of numbers of A40-
positive axonal varicosities showed 90% reduction in CmpE-
versus vehicle-treated mice (Fig. 7E) (one-sided t test, p 
0.0001). Biochemical quantification of RIPA-soluble A40 in
ipsilateral hippocampi and surrounding white matter showed
similar reduction (CmpE-treated mice, 32.5  2.87 pg/mg vs
vehicle-treated mice, 217.9  52.1 pg/mg; one-sided t test, p 
0.0013). CmpE effectively blocked -secretase activity in the set-
ting of TBI, as evidenced by similar levels of full-length APP but
increased -CTFs and -CTFs in cerebellar lysates of mice with
CmpE treatment (data not shown). Furthermore, numbers of
APP-stained varicosities were similar between treatment groups
(Fig. 7F,G,J). This finding demonstrated that -secretase inhibi-
tion by CmpE specifically reduced proteolytic A production,
rather than reducing A pathology by affecting extent of axonal
injury in these injured mice.
CmpE treatment had no effect on tau pathologies in 3xTg-AD
mice killed at 24 h after TBI, despite the 90% reduction in A




















































































Figure6. Controlled cortical impact TBI increased levels of phospho-tau immunoreactivity in ipsilateral hippocampi and fimbria
of young 3xTg-ADmice.A–D, Tau staining ofmoderate TBI (2.0mm) and sham 3xTg-ADmice using a polyclonal antibody against
phosphorylated tau at S199. Scale bar, 50 m. A, B, Ipsilateral hippocampal CA1. C, D, Ipsilateral fimbria. E–L, Phospho-tau
staining in fimbria of TBI and sham 3xTg-ADmice using polyclonal antibodies against tau phosphorylated at T205 (E, F ), T231 (G,
H ), S396 (I, J ), and S422 (K, L).M, Representative AT8Western blot of ipsilateral hippocampi from 2.0mmTBI and sham3xTg-AD
mice. AT8 blots were stripped and reprobed with Tau46 antibody for total tau. A significant increase in ratio of AT8 to Tau46 band
densities was observed after TBI (***p 0.0006, Mann–Whitney U test). N, Representative AT100 Western blot of ipsilateral
hippocampi from 2.0 mm TBI and sham 3xTg-AD mice. A significant increase in ratio of AT100 to Tau46 band densities was
observed after TBI (*p 0.03, Student’s t test).O, Representative AT180Western blot of ipsilateral hippocampi from 2.0mm TBI
and sham 3xTg-AD mice. A significant increase in ratio of AT180 to Tau46 band densities was observed after TBI (*p 0.03,
Student’s t test). n 7–8 mice per group. Error bars represent mean SEM.
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levels in injured 3xTg-AD mice treated with CmpE or vehicle.
Specifically, we studied tau pathology histologically with polyclonal
total tau antibody, phospho-S199 antibody against tau phosphory-
latedatS199, andPHF1antibodyagainstphosphorylated tauatS396
and S404.We also examined tau pathology biochemically viaWest-
ern blots using the AT8, AT100, and Tau46 antibodies. Finally, we
investigated total and phospho-S199 levels by ELISA. All assess-
ments were done in a blinded fashion.
Using quantitative stereological methods as described above,
we found that the numbers of total tau-positive puncta in the
ipsilateral fimbria, the numbers of total tau-stained somata in the
ipsilateral amygdala, and total length density of tau-positive CA1
processes were not affected by CmpE treatment in injured
3xTg-AD mice (Fig. 8A,B,E–G,J–L,O). Total tau levels in the
ipsilateral hippocampal tissues of injured mice treated with CmpE
were not statistically different from those of vehicle-treatedmice, as
assessed by human tau ELISA (CmpE-treated mice, 819.7 99.38
pg/mgvs vehicle-treatedmice, 796.6161.1pg/mg; Student’s t test,
p 0.9).
The increases in tau phosphorylation after TBI were not affected
by CmpE treatment. There were similar numbers of pS199- and
PHF1-positive tau puncta in ipsilateral fimbria of injured mice
treated with CmpE compared with vehicle-treatedmice (Fig. 8P,Q,
T,U,V,Y). Phospho-tau S199 levels in ipsilateral hippocampi as-
sessedbyELISArevealed similar levels inCmpE-andvehicle-treated
mice (CmpE group, 61.1  9.2 pg/mg vs
vehicle group, 57.9 13.9 pg/mg; Student’s
t test, p  0.85). Ipsilateral hippocampi of
CmpE- and vehicle-treated mice subjected
to Western blotting using AT8 and AT100
antibodies also corroborated these findings
(AT8/Tau 46 ratio for CmpE group, 1.01
0.04 vs vehicle group, 1.09 0.07; AT100/
Tau46 ratio forCmpEgroup, 1.01 0.03 vs
vehicle group,1.080.05).Taupathologies
in these experimental groups were qualita-
tively and quantitatively similar to those
seen in themoderately injuredmice that re-
ceived neither vehicle nor CmpE (Figs.
4–6). Thus, it was unlikely that there were
any effects of DMSO vehicle treatment or
the additional handling required for the
injections.
Furthermore, we examined the effects
of CmpE or vehicle treatment on injured
mice up to 7 d after TBI. We chose this
survival period because we found that
both A and tau abnormalities persisted
in untreated, injuredmice at 7 d after TBI,
although to a lesser extent than those ob-
served at 24 h after TBI. Mice received
CmpE or vehicle injections four times in
the first 24 h as described above and then
twice daily until they were killed at 7 d
after injury. We stained brain sections for
A40, APP, total tau, phospho-S199, and
PHF1 to assess the effects of CmpE treat-
ment on both A and tau abnormalities.
Extended CmpE treatment success-
fully blocked the accumulation of the A
in the ipsilateral fimbria/fornix of injured
3xTg-AD mice at 7 d (Fig. 7C–E) (one-
sided t test, p 0.001). In vehicle-treated
mice, there were still numerous A-positive (Fig. 7D) and APP-
positive (Fig. 7I) varicosities at 7 d, although the extent of stain-
ingwas reduced comparedwith 24 h after TBI (Fig. 7E, J). Similar
to the acute CmpE treatment experiments, extendedCmpE treat-
ment did not alter the extent of axonal injury as assessed by
numbers of APP-positive varicosities in the ipsilateral fimbria/
fornix (Fig. 7H–J). Furthermore, total tau immunoreactivity in
the fimbria, amygdala, and CA1 were not statistically different in
CmpE- and vehicle-treated mice (Fig. 8C–E,H–J,M–O). Impor-
tantly, tau phosphorylation at phospho-S199 and PHF1 epitopes
was also unaffected after 7 d of CmpE treatment (Fig. 8R–T,W–Y).
Thus, we did not observe a delayed effect of inhibition of A accu-
mulation on tau pathology after TBI.
In summary, inhibition of -secretase activity with CmpE suc-
cessfully blocked posttraumatic A generation and buildup in in-
juredaxons in3xTg-ADmicebutdidnotaffect either localordistant
tau immunoreactivity. This provides experimental evidence that
posttraumatic acceleration of A and tau pathologies occur inde-
pendently in this animal model.
Discussion
In summary, controlled cortical impact TBI in 3xTg-AD mice
recapitulated two key pathological features observed in human
TBI patients. First, rapid intra-axonal A accumulation was con-



























































































Figure 7. Systemic inhibition of -secretase activity with CmpE blocked posttraumatic A accumulation at 1 and 7 d after
injury but did not alter the extent of axonal injury. A, B, A40 immunohistochemistry (IHC) for injured 3xTg-AD mice receiving
CmpE or vehicle (DMSO) treatment killed at 24 h after injury. C, D, A40 IHC for injured 3xTg-ADmouse receiving CmpE or vehicle
treatment for 7 d after injury. E, Stereological quantification of numbers of A40-stained varicosities in the ipsilateral fimbria of
injured 3xTg-ADmice receiving either CmpE or vehicle treatment at 1 and 7 d after TBI. These data demonstrated intra-axonal A
buildup after TBI could be inhibited by blocking-secretase activity. ***p 0.0001; **p 0.0015, Student’s t test. F,G, APP IHC
of fimbria from injured 3xTg-ADmice treated with CmpE or vehicle killed at 24 h after injury.H, I, APP IHC of fimbria from injured
3xTg-ADmice treatedwith CmpE or vehicle for 7 d after injury. J, Stereological quantification of APP-positive axonal varicosities in
ipsilateral fimbria of injuredmice treatedwith CmpE or vehicle killed at 1 and 7 d after TBI. Similar numbers of APP-positive axonal
varicosities in the two treatment groups indicate CmpE treatment did not affect the extent of axonal injury in thesemice. n 7–8
mice per group. Error bars represent mean SEM.
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fimbria. This is similar to the intra-axonal
A accumulation observed in human TBI
patients (D. H. Smith et al., 2003; Ikono-
movic et al., 2004; Uryu et al., 2007; Chen
et al., 2009). No such accumulation is ex-
pected at this age, and none was seen in
sham-injured mice. Second, increased
tau immunoreactivity was found in
three distinct brain regions of moderately
injured 3xTg-ADmice. There was immu-
nohistochemical and biochemical evi-
dence for increased tau accumulation and
phosphorylation induced by TBI at sev-
eral epitopes.
Axonal injury appears necessary for
posttraumatic A accumulation in this
model, as the extent of intra-axonal A
accumulation correlated well with injury
severity and noAwas detected immuno-
histochemically in areas without axonal
injury. A was found colocalized with the
axonal injurymarkers APP andNFL-68 in
injured 3xTg-AD mice. Histological find-
ings of A accumulation after TBI were
further confirmed biochemically; there
was approximately twice the amount of
insoluble total A and A40 in ipsilateral
hippocampal tissues of moderately in-
jured comparedwith uninjuredmice. The
significant increase in only A40 levels af-
ter TBI in these micemay be related to the
lack of extracellular A plaques observed
by immunohistochemistry.
In addition to focal injuries, the con-
trolled cortical impact TBI model used in
this study also affected distant regions
such as the contralateral hippocampi and
ipsilateral amygdala. Evidence for this ob-
servation included a significant increase
in total tau accumulation in the contralat-
eral CA1 and ipsilateral amygdala ofmod-
erately injured mice. Interestingly, there
was not a substantial increase in total tau
accumulation in the ipsilateral hippocam-
pus. Neuronal loss or injury may have
caused release of tau into the extracellular
space where it could not be detected by
immunohistochemistry.
The subacute effects of TBI are evi-






























































































































































































































Figure8. Inhibition of posttraumatic A formationby CmpEdid not affect tau pathology aftermoderate (2.0mm) TBI in young
3xTg-AD mice. A–N, Total tau immunohistochemistry (IHC) in the ipsilateral fimbria (A–D), ipsilateral amygdala (F–I ), and
contralateral CA1 (K–N ) of mice treated with CmpE or vehicle killed at 1 or 7 d after injury. Stereological quantification of total
tau-stained puncta in ipsilateral fimbria (E), total tau-stained somata in ipsilateral amygdala (J ), and total tau-stained neurite
4
length density in contralateral CA1 (O) of injuredmice treated
with CmpE or vehicle at 1 and 7 d post TBI is shown. P–S,
Phospho-tau IHC using pS199 antibody. T, Stereological quan-
tification of pS199-positive puncta in ipsilateral fimbria of
mice treated with CmpE or vehicle. U–X, Phospho-tau IHC us-
ing PHF1 antibody. Y, Stereological quantification of PHF1-
positive tau puncta in ipsilateral fimbria of injured mice
treated with CmpE or vehicle. All measures of tau immunore-
activity were not statistically different between CmpE- and
vehicle-treatedmice (Mann–WhitneyU tests). n 7–8mice
per group. Error bars represent mean SEM.
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ity of APP, A, total tau, and phospho-tau in injured 3xTg-AD
mice killed at 7 d after injury. However, there was less APP, A,
and total tau immunoreactivity at 7 d compared with 24 h after
TBI, presumably because of progressive cell death and tissue loss
at the affected regions at the later time point. Interestingly, tau
phosphorylation at phospho-S199 and PHF1 epitopes remained
elevated at 7 d after injury. This suggests a possible role for path-
ological tau on longer-term outcomes after TBI in vivo.
Importantly, inhibition of enzymatic activity of -secretase,
one of the canonical enzymes involved in cleaving APP to form
A under physiological conditions, almost completely elimi-
nated posttraumatic A aggregation in injured 3xTg-AD. How-
ever, accelerated tau abnormalities observed after trauma in these
mice appear likely to be independent of A, since inhibition of
intra-axonal A buildup did not alter tau pathology. These find-
ings were consistent during the acute (24 h) as well as the sub-
acute (7 d) periods after TBI. This demonstrates the utility of
this controlled cortical impact 3xTg-AD model in the mecha-
nistic investigation of the association between TBI and AD-
related pathology.
Together, these results support a causal relationship between
TBI and acceleration of A and tau pathologies. Our mouse
model is the first small-animalmodel, of whichwe are aware, that
reliably and rapidly reproduces these key features of acute human
post-TBI A and tau pathologies. This could be attributable to a
number of reasons. First, previous TBI models using transgenic
mice only used those that overexpress either mutated forms of
APP or tau, not both (Smith et al., 1998; Uryu et al., 2002; Yo-
shiyama et al., 2005). Second, 3xTG-AD mice also have a
knock-in PS1 mutation, which shifts A accumulation to mostly
intracellular (Mastrangelo and Bowers, 2008) and possibly in-
creases tau phosphorylation (Baki et al., 2004; Dewachter et al.,
2008). Furthermore, methodological differences between our
stereotaxic electromagnetically driven controlled cortical impact
device-based protocol and previously used injury paradigms
could have resulted in different distributions of axonal injury or
other subtle differences in postinjury physiology.
However, there are several limitations of our TBImodel. First,
this model produces a central contusion and pericontusional ax-
onal injury. Humans often do sustain contusions with pericon-
tusional axonal injury, butmany injuries in humans are diffuse or
multifocal. Nonetheless, axonal injury appears to be a virtually
ubiquitous sequela of TBI (Adams, 1982; Gennarelli et al., 1982;
Gennarelli, 1983, 1993; Adams et al., 1984; Blumbergs et al., 1994,
1995; Geddes et al., 2000), and many types of injuries in humans
have been reported to result in A and tau pathology (Roberts et
al., 1991; Schmidt et al., 2001; D. H. Smith et al., 2003; Ikono-
movic et al., 2004; Uryu et al., 2007; McKee et al., 2009). Injured
axons appear to be a major source of A after TBI in humans
(D. H. Smith et al., 2003; Ikonomovic et al., 2004; Uryu et al.,
2007; Chen et al., 2009), pigs (Smith et al., 1999; Chen et al.,
2004), rats (Iwata et al., 2002), and now mice. Therefore, robust
axonal injury and intra-axonal A accumulation lends support to
the validity of our model. An additional mouse injury paradigm
such as fluid percussion or impact acceleration injury that pro-
duces more diffuse axonal injury will be required to generalize
our findings.
Second, most humans with TBI do not have a known genetic
predisposition to developing AD-related pathologies, whereas
the 3xTg-AD line has three mutations implicated in familial de-
mentia. This limitation applies to this and othermousemodels of
age-related AD pathology as well. The introduction of these mu-
tations seems to be required because of fundamental differences
betweenmouse and human coding sequences, differences in gene
regulation, the short life span of the mouse, or a combination of
these. Mice with human wild-type APP, PS1, and tau alleles
“knocked in” to the mouse loci would be useful to differentiate
these possibilities.
Third, whereas axonal tau accumulation has been observed in
a few cases of acute TBI in humans, the effects of injury severity
on axonal tau accumulation, as described in this study, have not
been documented. Likewise, the increased somatic tau accumu-
lation in this model is rarely observed in human TBI (Ikono-
movic et al., 2004). Thus, the relevance of these pathologies is not
known.
Fourth, neither this animalmodel, nor any other small animal
of whichwe are aware, develops acute posttraumatic extracellular
A plaque pathology. The relative importance of extracellular
versus intracellular A pathologies in the setting of TBI is not
known. Nonetheless, the opportunity to investigate one form of
acute posttraumatic A pathology, acute posttraumatic tau ab-
normalities, and the interaction of these two pathologies makes
the model presented here a significant advance. Ultimately, full
validation will require predictions made based on the model that
are subsequently confirmed in humans.
The question of whether these pathologies trigger chronic,
progressive neurodegeneration remains to be addressed. Simi-
larly, future studies should be performed to determine whether
these A and tau abnormalities adversely affect behavioral out-
comes in 3xTg-AD mice subjected to TBI. If so, preclinical ther-
apeutic trials would be required to determine whether clinically
realistic interventions could ameliorate these deficits (Abraham-
son et al., 2006; Loane et al., 2009). The long-term goal would be
to develop treatments that block the adverse effects of AD-related
pathophysiological processes after acute TBI in humans.
Based on our findings, it is most likely that A does not play a
critical role in TBI-induced tau pathology. However, a small frac-
tion of A remained after -secretase inhibition in injured
3xTg-AD mice. Thus, there may be minor, yet toxic, A species
that could ultimately affect tau pathology. Additional studies
should be performed to identify whether such species exist and
whether they do, in fact, accelerate tau pathology in the setting of
TBI. Experiments involving TauP301L-only transgenic mice or
3xTg-AD, BACE/mice subjected to TBI would provide fur-
ther insights into effects of TBI on tau pathology. If, as seems
likely, tau pathology is truly independent of A in the setting of
TBI, the underlyingmechanismswill require investigation to elu-
cidate additional therapeutic targets. Possible involvement of
GSK3, calpain, JNK, and cdk5 cascades on tau pathology could
be considered (Querfurth and LaFerla, 2010).
Apart from its effects on A production, mutant PS1 has been
implicated in other functions such as neuronal calcium dysho-
meostasis and regulation of synaptic plasticity (Thinakaran and
Parent, 2004;Mattson, 2010). Since dysregulation of calcium sig-
naling is thought to play an important role in glutamate-induced
excitotoxicity after brain injury (Arundine and Tymianski, 2004;
Szydlowska and Tymianski, 2010), it is possible that the mutant
PS1 in the 3xTg-AD mouse model may exacerbate TBI-induced
neurodegeneration, in addition to its effects on both A and tau
pathologies. Future experiments subjecting PS1 single-transgenic
mouse to brain trauma will be required to elucidate its role in the
context of TBI.
In conclusion, this controlled cortical impact model using
3xTg-ADmice reproduced key features of human post-TBI AD-
related pathology. It will likely allow many mechanistic hypoth-
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eses to be tested and may be useful for preclinical therapeutic
development.
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